期刊
BIOMOLECULES
卷 13, 期 5, 页码 -出版社
MDPI
DOI: 10.3390/biom13050747
关键词
immunomodulatory imide drugs (IMiDs); thalidomide; pomalidomide; neuroinflammation; cereblon; traumatic brain injury; Alzheimer's disease; Parkinson's disease; neurodegeneration; erythema nodosum leprosum
The immunomodulatory imide drug (IMiD) class, consisting of thalidomide and its derivatives lenalidomide and pomalidomide, has greatly improved the treatment of specific cancers and possesses potent anticancer and anti-inflammatory actions. These actions are mainly mediated by the binding of IMiDs to the human protein cereblon, resulting in the modification of protein degradation and the emergence of new substrate proteins. However, this binding also leads to adverse effects, including teratogenicity.
The immunomodulatory imide drug (IMiD) class, which includes the founding drug member thalidomide and later generation drugs, lenalidomide and pomalidomide, has dramatically improved the clinical treatment of specific cancers, such as multiple myeloma, and it combines potent anticancer and anti-inflammatory actions. These actions, in large part, are mediated by IMiD binding to the human protein cereblon that forms a critical component of the E3 ubiquitin ligase complex. This complex ubiquitinates and thereby regulates the levels of multiple endogenous proteins. However, IMiD-cereblon binding modifies cereblon's normal targeted protein degradation towards a new set of neosubstrates that underlies the favorable pharmacological action of classical IMiDs, but also their adverse actions-in particular, their teratogenicity. The ability of classical IMiDs to reduce the synthesis of key proinflammatory cytokines, especially TNF-a levels, makes them potentially valuable to reposition as drugs to mitigate inflammatory-associated conditions and, particularly, neurological disorders driven by an excessive neuroinflammatory element, as occurs in traumatic brain injury, Alzheimer's and Parkinson's diseases, and ischemic stroke. The teratogenic and anticancer actions of classical IMiDs are substantial liabilities for effective drugs in these disorders and can theoretically be dialed out of the drug class. We review a select series of novel IMiDs designed to avoid binding with human cereblon and/or evade degradation of downstream neosubstrates considered to underpin the adverse actions of thalidomide-like drugs. These novel non-classical IMiDs hold potential as new medications for erythema nodosum leprosum (ENL), a painful inflammatory skin condition associated with Hansen's disease for which thalidomide remains widely used, and, in particular, as a new treatment strategy for neurodegenerative disorders in which neuroinflammation is a key component.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据